JP2015530359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530359A5 JP2015530359A5 JP2015521668A JP2015521668A JP2015530359A5 JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5 JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- item
- tumors
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669967P | 2012-07-10 | 2012-07-10 | |
| US61/669,967 | 2012-07-10 | ||
| US201261702916P | 2012-09-19 | 2012-09-19 | |
| US61/702,916 | 2012-09-19 | ||
| PCT/US2013/049368 WO2014011489A2 (en) | 2012-07-10 | 2013-07-03 | Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530359A JP2015530359A (ja) | 2015-10-15 |
| JP2015530359A5 true JP2015530359A5 (enExample) | 2016-08-25 |
| JP6336696B2 JP6336696B2 (ja) | 2018-06-06 |
Family
ID=49916655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521668A Active JP6336696B2 (ja) | 2012-07-10 | 2013-07-03 | がんおよび自己免疫疾患の診断および治療に使用するためのモノクローナル抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9926380B2 (enExample) |
| EP (2) | EP3088421B1 (enExample) |
| JP (1) | JP6336696B2 (enExample) |
| KR (1) | KR102049222B1 (enExample) |
| CN (1) | CN104540522B (enExample) |
| AU (1) | AU2013288982B2 (enExample) |
| CA (1) | CA2883056C (enExample) |
| CY (1) | CY1121743T1 (enExample) |
| DK (1) | DK3088421T3 (enExample) |
| EA (1) | EA034033B1 (enExample) |
| ES (1) | ES2720291T3 (enExample) |
| HR (1) | HRP20190939T1 (enExample) |
| HU (1) | HUE043443T2 (enExample) |
| IL (1) | IL236664B (enExample) |
| IN (1) | IN2015DN00263A (enExample) |
| LT (1) | LT3088421T (enExample) |
| MX (1) | MX360984B (enExample) |
| PH (1) | PH12015500074A1 (enExample) |
| PL (1) | PL3088421T3 (enExample) |
| PT (1) | PT3088421T (enExample) |
| RS (1) | RS58755B1 (enExample) |
| SI (1) | SI3088421T1 (enExample) |
| UA (1) | UA114108C2 (enExample) |
| WO (1) | WO2014011489A2 (enExample) |
| ZA (1) | ZA201500247B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
| LT3132247T (lt) * | 2014-04-16 | 2021-12-10 | Juno Therapeutics Gmbh | Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| CN108474791B (zh) | 2015-10-22 | 2022-07-08 | 朱诺治疗学有限公司 | 培养细胞的方法及用于该方法的试剂盒和设备 |
| HK1258932A1 (zh) | 2015-10-22 | 2019-11-22 | Juno Therapeutics Gmbh | 用於转导的方法、反应剂盒、反应剂和设备 |
| US11466253B2 (en) | 2015-10-22 | 2022-10-11 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| SG11201802769RA (en) | 2015-10-29 | 2018-05-30 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| MA49288A (fr) | 2017-04-27 | 2020-03-04 | Juno Therapeutics Gmbh | Reactifs particulaires oligomères et leurs méthodes d'utilisation |
| US12290564B2 (en) | 2017-05-18 | 2025-05-06 | Renovorx, Inc. | Methods and apparatuses for treating tumors |
| KR20200021074A (ko) | 2017-06-14 | 2020-02-27 | 아디셋 바이오, 인크. | Hla 제한된 방식으로 hla-a2/tyrd를 결합할 수 있는 항체 및 이의 용도 |
| CN108611322B (zh) * | 2018-05-09 | 2020-02-11 | 邹畅 | 乳腺癌循环肿瘤细胞系ctc-3、培养基及ctc-3的建立方法和应用 |
| SG11202101204TA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Processes for generating engineered cells and compositions thereof |
| EP3874024A1 (en) | 2018-10-31 | 2021-09-08 | Juno Therapeutics GmbH | Methods for selection and stimulation of cells and apparatus for same |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| US20230192824A1 (en) * | 2020-04-02 | 2023-06-22 | United States Of America As Represented By The Secretary Of The Navy | Antigen Binding Proteins to Class 5 ETEC Adhesins |
| GB202008860D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CA3227281A1 (en) * | 2021-07-26 | 2023-02-02 | Michael H. Cardone | Methods and compositions related to mcl-1 and bim heterodimer antibodies |
| WO2024102497A2 (en) * | 2022-11-11 | 2024-05-16 | Renovorx, Inc. | Methods and apparatuses for delivering an agent through the vasa vasorum |
| WO2025049921A1 (en) * | 2023-08-30 | 2025-03-06 | University Of Louisville Research Foundation, Inc. | Methods for single molecule resolution of near full-length immunoglobulin heavy and light chain repertoires |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| WO1990007332A1 (fr) | 1986-04-25 | 1990-07-12 | Hitoshi Shichi | Agent immunosuppresseur |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| FR2658197B1 (fr) | 1990-02-14 | 1992-05-22 | Inst Nat Sante Rech Med | Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement. |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US7074904B2 (en) | 1994-07-29 | 2006-07-11 | Altor Bioscience Corporation | MHC complexes and uses thereof |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO2000023087A1 (en) | 1998-10-21 | 2000-04-27 | Sunol Molecular Corporation | Polyspecific binding molecules and uses thereof |
| CA2487779C (en) | 2001-06-05 | 2012-10-02 | Altor Bioscience Corporation | P53 binding t cell receptor molecules and uses thereof |
| HU228957B1 (en) | 2001-07-02 | 2013-07-29 | Aimsco Ltd | Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| ATE414105T1 (de) | 2002-10-11 | 2008-11-15 | Chugai Pharmaceutical Co Ltd | Zelltod-induzierender wirkstoff |
| US20060167230A1 (en) * | 2003-01-20 | 2006-07-27 | Takaki Koga | Anti-pci neutralizing antibody |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| KR20060130606A (ko) | 2003-12-12 | 2006-12-19 | 추가이 세이야쿠 가부시키가이샤 | 세포사 유도제 |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090042285A1 (en) | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
| US20060045884A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents | Vaccines for autoimmune and infectious disease |
| US20060045881A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| CA2603264C (en) | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| WO2006123724A1 (ja) | 2005-05-18 | 2006-11-23 | The University Of Tokushima | 抗hla抗体を利用した新規医薬品 |
| CA2662798A1 (en) | 2005-09-07 | 2007-03-15 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| CL2007002057A1 (es) | 2006-07-13 | 2008-01-11 | Chugai Pharmaceutical Co Ltd | Diacuerpo anti-antigeno leucocitario humano (hla), usos del diacuerpo para preparar un medicamento util como inductor de muerte celular, supresor del crecimeinto celular o como agente antitumoral. |
| CL2008000719A1 (es) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| WO2009073163A1 (en) * | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| WO2010065962A2 (en) * | 2008-12-05 | 2010-06-10 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease |
| TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
-
2013
- 2013-03-07 UA UAA201501025A patent/UA114108C2/uk unknown
- 2013-07-03 US US14/413,833 patent/US9926380B2/en active Active
- 2013-07-03 IN IN263DEN2015 patent/IN2015DN00263A/en unknown
- 2013-07-03 LT LTEP16152641.3T patent/LT3088421T/lt unknown
- 2013-07-03 AU AU2013288982A patent/AU2013288982B2/en active Active
- 2013-07-03 EA EA201590187A patent/EA034033B1/ru not_active IP Right Cessation
- 2013-07-03 CA CA2883056A patent/CA2883056C/en active Active
- 2013-07-03 HU HUE16152641A patent/HUE043443T2/hu unknown
- 2013-07-03 MX MX2015000450A patent/MX360984B/es active IP Right Grant
- 2013-07-03 EP EP16152641.3A patent/EP3088421B1/en active Active
- 2013-07-03 WO PCT/US2013/049368 patent/WO2014011489A2/en not_active Ceased
- 2013-07-03 SI SI201331371T patent/SI3088421T1/sl unknown
- 2013-07-03 JP JP2015521668A patent/JP6336696B2/ja active Active
- 2013-07-03 DK DK16152641.3T patent/DK3088421T3/da active
- 2013-07-03 PT PT16152641T patent/PT3088421T/pt unknown
- 2013-07-03 RS RS20190609A patent/RS58755B1/sr unknown
- 2013-07-03 EP EP13816335.7A patent/EP2872174A2/en not_active Withdrawn
- 2013-07-03 KR KR1020157003610A patent/KR102049222B1/ko active Active
- 2013-07-03 CN CN201380042522.1A patent/CN104540522B/zh active Active
- 2013-07-03 PL PL16152641T patent/PL3088421T3/pl unknown
- 2013-07-03 ES ES16152641T patent/ES2720291T3/es active Active
-
2015
- 2015-01-11 IL IL236664A patent/IL236664B/en active IP Right Grant
- 2015-01-12 PH PH12015500074A patent/PH12015500074A1/en unknown
- 2015-01-14 ZA ZA2015/00247A patent/ZA201500247B/en unknown
-
2018
- 2018-02-13 US US15/895,782 patent/US11192958B2/en active Active
-
2019
- 2019-05-07 CY CY20191100490T patent/CY1121743T1/el unknown
- 2019-05-21 HR HRP20190939TT patent/HRP20190939T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7849417B2 (ja) | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 | |
| ES2968880T3 (es) | Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo | |
| ES2778651T3 (es) | Receptores de antígeno quimérico y métodos de uso | |
| AU2014225788B2 (en) | Engager cells for immunotherapy | |
| US20210252056A1 (en) | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective immunotherapy | |
| JP2022501043A (ja) | 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法 | |
| JP7035170B2 (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| JP2024178177A (ja) | 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法 | |
| CN113286879A (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| CN106478809B (zh) | 识别prame抗原短肽的tcr | |
| JP2020533958A (ja) | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 | |
| CN106632660A (zh) | 识别ny‑eso‑1抗原短肽的tcr | |
| JP2024054286A (ja) | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 | |
| JP2022513682A (ja) | 抗ｃｄ３８免疫療法によりがんを処置するための組成物および方法 | |
| JP2022535005A (ja) | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 | |
| EP3957650A1 (en) | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation | |
| AU2013271428A1 (en) | Human bispecific EGFRvIII antibody engaging molecules | |
| CN114195894A (zh) | 一种靶向4-1bb的抗体及其应用 | |
| US20220242960A1 (en) | Ghr-106 chimeric antigen receptor construct and methods of making and using same | |
| US9611321B2 (en) | Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies | |
| CN106478808B (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
| CN106632658A (zh) | 识别ny-eso-1抗原短肽的tcr | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| CN106188274A (zh) | 识别rhamm抗原短肽的t细胞受体 | |
| CN113423822A (zh) | Psca car-t细胞 |